AviadoBio
AviadoBio is a London-based clinical-stage gene therapy company developing one-time AAV-based treatments for neurodegenerative disorders, including AVB-101 in Phase 1/2 for FTD-GRN, leveraging its proprietary vMiX RNAi silencing platform licensed from King's College London.
- Company typePrivate
- Founded2019
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AviadoBio does
AviadoBio is a London-headquartered, clinical-stage gene therapy company founded in 2019 to develop one-time, disease-modifying AAV-based treatments for neurodegenerative disorders with high unmet need. The company was spun out of King's College London and the UK Dementia Research Institute and operates with 11–50 employees across the UK and the United States. Its pipeline is anchored by AVB-101, an AAV gene supplementation therapy delivered via minimally invasive intrathalamic infusion that is currently in Phase 1/2 development (ASPIRE-FTD trial) for frontotemporal dementia with GRN mutations (FTD-GRN), and extends into AVB-406 (vMiX™ RNAi silencing of MAPT for Alzheimer's disease and tauopathies, preclinical with planned 2026 clinical entry), UGX-202 (an optogenetic AAV gene therapy for retinitis pigmentosa licensed from UgeneX Therapeutics in October 2025), and AVB-205 (an ATXN2-targeting preclinical construct for ALS).
AviadoBio's core technology is the proprietary vMiX™ vectorized RNAi gene silencing platform, exclusively licensed from King's College London and expanded in June 2026 to cover all human therapeutic areas. vMiX combines AAV-delivered RNAi payloads with cell- and tissue-specific promoters to enable one-time, durable silencing of up to three genes and supports silencing-and-replacement constructs. Delivery innovation includes the intrathalamic approach (leveraging the thalamus as a CNS relay hub for broad cortical expression of progranulin) and a BBB-penetrant AAV capsid using the human transferrin receptor 1 for systemic CNS exposure in AVB-406.
The company is pre-revenue and has no commercial products; its near-term economic model rests on milestone-based licensing and partnerships rather than product sales. Capital is sourced from an $80M seed round (December 2021), a $20M equity investment plus up to $30M upfront from Astellas under a now-lapsed exclusive option for AVB-101, strategic grants from the Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration, and contingent milestone payments from the UgeneX UGX-202 deal worth up to $413M. Go-to-market is enterprise-led: a Phase 1/2 clinical trial operating at multiple international sites, scientific-conference-driven visibility (ASGCT, AAIC, ESGCT, ISFTD), and a stated intent to pursue strategic partnerships to advance vMiX-enabled programs into cardiovascular, nephrology, oncology, and other newly licensed therapeutic areas.
AviadoBio firmographics
Firmographics- Name
- AviadoBio
- Legal name
- AviadoBio Limited
- Website
- https://aviadobio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AviadoBio is a London-based clinical-stage gene therapy company developing one-time AAV-based treatments for neurodegenerative disorders, including AVB-101 in Phase 1/2 for FTD-GRN, leveraging its proprietary vMiX RNAi silencing platform licensed from King's College London.
- Ownership category
- akta.pro rank
AviadoBio industry classification
Industry- Product category
- Gene Therapy for Neurodegenerative Diseases
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
- akta.pro primary industry
- Neurology/CNS Gene Therapies (HLAAACAH)
- akta.pro secondary industries
- AAV Vector Gene Therapy Developers (HLAAACAA), Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
Keywords
Where AviadoBio is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
AviadoBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Gene Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, AviadoBio is developing gene therapies for neurodegenerative diseases. The company has received strategic investments from ADDF and AFTD, and previously had an exclusive option agreement with Astellas worth up to $2.18 billion plus royalties. Revenue will come from commercialization of approved gene therapies.
- Platform Licensing and Partnerships: Expanded vMiX platform license with King's College London enables strategic collaborations and partnerships across cardiovascular disease, nephrology, oncology and other indications beyond the company's core neuroscience focus.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
AviadoBio product offering
Product offeringCore offering
AviadoBio is a clinical-stage gene therapy company developing investigational AAV-based, one-time gene therapies for neurodegenerative diseases. Its lead program, AVB-101, delivers a functional GRN gene via intrathalamic infusion for frontotemporal dementia with GRN mutations (FTD-GRN), currently in Phase 1/2 ASPIRE-FTD clinical trial. The company also advances AVB-406 (tau gene silencing for Alzheimer's), UGX-202 (optogenetic therapy for retinitis pigmentosa), AVB-205 (ALS), and its proprietary vMiX RNAi platform for one-time, durable gene silencing across CNS and retinal indications.
Product overview
AviadoBio is a gene therapy company developing targeted, one-time AAV-based gene therapies for neurodegenerative disorders. The company's pipeline centers on AVB-101 (gene supplementation for FTD-GRN in Phase 1/2), AVB-406 (vMiX-powered RNAi for tau silencing in Alzheimer's disease, entering clinical stage), and UGX-202 (optogenetic therapy for retinitis pigmentosa in preclinical stage). The proprietary vMiX™ RNAi platform enables precision gene silencing with applications across multiple therapeutic areas. Delivery approaches include intrathalamic administration for brain targets, intravenous delivery with BBB-crossing capsids, and intravitreal delivery for retinal diseases.
Differentiator
Problem solved
Functional benefit
Brands
- vMiX™: Proprietary vectorized RNA interference (RNAi) gene silencing platform for one-time, durable gene silencing using AAV delivery
Products and services
- AVB-101
Quantifiable outcome
- Up to 80% MAPT mRNA knockdown in brain cortex tissue in humanized mice
- +3 more outcomes
Companies that use AviadoBio
Customer profileSegments4 records
Ideal customer profiles2 records
AviadoBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
AviadoBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- King's College LondoncoreExpanded exclusive license agreement providing AviadoBio rights to apply the vMiX RNAi gene silencing platform across all human therapeutic areas, extending beyond the original 2020 agreement focused on neurological diseases. The expansion opens potential applications across cardiovascular disease, nephrology, oncology and other indications. AviadoBio has been optimizing the vMiX platform since 2020 and developed an efficient discovery engine workflow for rapid progression of development candidates.
- UgeneX TherapeuticssupportingAgreement to license UGX-202, a gene therapy for retinitis pigmentosa, committing up to $413 million for development and sales milestones. The therapy uses an AAV viral vector to restore vision by reprogramming retinal cells and is set to enter clinical development. This expands AviadoBio's pipeline in genetic therapies for neurodegenerative and eye diseases.
- Astellas PharmacoreExclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with progranulin mutations. AviadoBio received $20 million equity investment and up to $30 million in upfront payments, with potential milestone payments of up to $2.18 billion plus royalties if Astellas exercises its option. The collaboration combined AviadoBio's gene therapy expertise with Astellas' global development and commercialization capabilities. AviadoBio has since regained full worldwide rights to AVB-101 following expiration of Astellas' exclusive option in 2024.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
AviadoBio competitors and assessment
Company assessmentDirect peers
- Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS diseases including Parkinson's, Huntington's, and Alzheimer's, with proprietary capsid engineering and RNAi approaches directly comparable to AviadoBio's vMiX platform and pipeline.
- uniQure: Clinical-stage AAV gene therapy developer with programs in Huntington's disease and ALS, sharing AviadoBio's AAV delivery approach and CNS neurodegenerative disease focus.
- Lexeo Therapeutics: Clinical-stage gene therapy company with CNS and cardiac disease programs using AAV delivery, comparable in stage, modality, and target indications to AviadoBio's pipeline.
- Prevail Therapeutics (Eli Lilly): AAV gene therapy developer acquired by Eli Lilly with FTD-GRN and Parkinson's programs, directly competing with AVB-101 in the same indication with similar gene supplementation approach.
- MeiraGTx: Clinical-stage AAV gene therapy company with CNS, ocular, and salivary gland programs, sharing AviadoBio's diversification across neurodegenerative and ophthalmology indications.
- Sangamo Therapeutics: Genomic medicine company developing AAV-delivered gene therapies for CNS and rare diseases, comparable in modality and clinical-stage status to AviadoBio.
Broad incumbents
- Eli Lilly: Large pharmaceutical company with significant neurodegenerative disease pipeline through Prevail Therapeutics acquisition, developing competing AAV gene therapy in FTD-GRN and broader Alzheimer's programs.
- Pfizer: Large pharmaceutical company with gene therapy capabilities and CNS pipeline, overlapping with AviadoBio's neurodegenerative focus areas and representing both potential competitor and partner.
Others
- Astellas Pharma: Former strategic partner of AviadoBio for AVB-101 with exclusive option that expired in 2024; a major CNS-focused pharmaceutical company that may re-engage or compete with similar gene therapy programs.
Emerging players
- BlueRock Therapeutics (Bayer): Bayer-owned cell and gene therapy company with Parkinson's and CNS programs using AAV and cell therapy approaches, representing an emerging competitor in neurodegenerative gene therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
AviadoBio social profiles
Digital presenceAviadoBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
AviadoBio leadership team
Management profileNumber of profiles
Profiles8 records
AviadoBio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AviadoBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AviadoBio
What does AviadoBio do?
AviadoBio is a clinical-stage gene therapy company developing investigational AAV-based, one-time gene therapies for neurodegenerative diseases. Its lead program, AVB-101, delivers a functional GRN gene via intrathalamic infusion for frontotemporal dementia with GRN mutations (FTD-GRN), currently in Phase 1/2 ASPIRE-FTD clinical trial. The company also advances AVB-406 (tau gene silencing for Alzheimer's), UGX-202 (optogenetic therapy for retinitis pigmentosa), AVB-205 (ALS), and its proprietary vMiX RNAi platform for one-time, durable gene silencing across CNS and retinal indications.
Is AviadoBio a public or private company?
AviadoBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was AviadoBio founded?
AviadoBio was founded in 2019. It employs 11 to 50 people.
Where is AviadoBio based?
AviadoBio is headquartered in London, United Kingdom, in the Europe region.
How does AviadoBio make money?
Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are platform Licensing and Partnerships.
Who are AviadoBio's main competitors?
Direct peers on record are Voyager Therapeutics, uniQure, Lexeo Therapeutics, Prevail Therapeutics (Eli Lilly), MeiraGTx and Sangamo Therapeutics. Broad incumbents are Eli Lilly and Pfizer. Astellas Pharma is listed as an others. BlueRock Therapeutics (Bayer) is listed as an emerging player.
Does AviadoBio have an API?
No public API is recorded for AviadoBio.
What industry is AviadoBio in?
AviadoBio's product category is Gene Therapy for Neurodegenerative Diseases. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714.